Malignant Neoplasm — Trials

Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20,116
Recruiting: 10,894
Ph III recruiting: 1,280
Growth YoY: +12%
Industry share: 20%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11,163)

clinicaltrialsPublishedShowing 201–250 of 6,256 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06169215	Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma	active not recruiting	Phase 2	58	National Cancer Institute (NCI)NIH	1	Sep 25, 2026	clinicaltrials
NCT06208150	A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide(MonumenTAL-6)	active not recruiting	Phase 3	838